Key clinical point: A higher body mass index (BMI) was not linked directly to survival outcomes but was linked to worse prognostic clinicopathologic variables in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) invasive lobular carcinoma (ILC) of the breast.
Major finding: Although BMI was not directly associated with disease-free survival and overall survival outcomes (both P = .08), a higher BMI was associated with larger tumor size (≥2 cm; P < .001), higher tumor grade (grade 3; P = .014), nodal involvement ( P < .001), and multifocal BC ( P = .01), which indicated significantly worsened prognosis.
Study details: This multicenter, retrospective study included 2490 patients with ER+/HER2− ILC of the breast, of which 1410, 712, and 368 patients were lean, overweight, and obese, respectively.
Disclosures: This study was funded by the Luxembourg Cancer Foundation and other sources. The authors declared no conflicts of interest.
Source: Baelen KV, Nguyen H-L, et al. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer. Eur J Cancer. 2023;112988 (Jul 12). Doi: 10.1016/j.ejca.2023.112988